TABLE 3.
Endpoint events and other drugs disposition.
| Intervention | ||||||
|---|---|---|---|---|---|---|
| LPV/r | HCQ | LPV/r + HCQ | SoC | p-value a | Total | |
| N = 124 | N = 109 | N = 244 | N = 113 | N = 590 | ||
| Events, n (%) | ||||||
| Invasive ventilation | 23 (18.5%) | 8 (7.3%) | 37 (15.2%) | 11 (9.7%) | 0.04 | 79 (13.4%) |
| Death | 21 (16.9%) | 12 (11.0%) | 27 (11.1%) | 15 (13.3%) | 0.41 | 75 (12.7%) |
| Invasive ventilation/death | 36 (29.0%) | 19 (17.4%) | 51 (20.9%) | 23 (20.4%) | 0.15 | 129 (21.9%) |
| Noninvasive ventilation/invasive ventilation/death | 38 (30.7%) | 23 (21.1%) | 61 (25.0%) | 26 (23.0%) | 0.36 | 148 (25.0%) |
| Stop of shedding | 50 (47.6%) | 41 (47.7%) | 117 (56.0%) | 42 (59.2%) | 0.26 | 250 (53.1%) |
| Other drugs, n (%) | ||||||
| Anticoagulants | 46 (37.1%) | 69 (63.3%) | 107 (43.9%) | 55 (48.7%) | 0.0005 | 227 (47.0%) |
| Steroids | 64 (51.6%) | 26 (23.9%) | 81 (33.2%) | 25 (22.1%) | <0.0001 | 196 (33.2%) |
| Azithromycin | 45 (36.3%) | 27 (24.8%) | 35 (14.3%) | 25 (22.1%) | <0.0001 | 132 (22.4%) |
| Immunomodulatory drugs | 20 (16.1%) | 18 (16.5%) | 51 (20.9%) | 3 (2.7%) | 0.0002 | 92 (15.6%) |
a
Chi-square test.